April 14, 2005 – Given the overall market slide, biotech scored a relative victory by dropping just .47% today. A 15 point fall in the Centient Biotech 200 was fairly benign in light of market-wide indexes, which dropped 1% or more to new 2005 lows. The CBT 200 index closed at 3105.25. The NYSE Composite was .98% lower and Nasdaq gave up 1.40%. Two companies today released positive data about hepatitus C treatments: Human Genome and Idenix, Crucell announced another US government contract, EntreMed won a second orphan drug designation for Panzem, Curis extended its collaboration with Genentech, and Avanir released strong numbers for its pseudobulbar drug. More details...
